Money-saving cefuroxime reduces endophthalmitis

Article

An investigation has revealed that the administration of intracameral cefuroxime reduces endophthalmitis in cataract surgery and has a high clinical and economical impact on prevention for the infection.

An investigation has revealed that the administration of intracameral cefuroxime reduces endophthalmitis in cataract surgery and has a high clinical and economical impact on prevention of the infection.

A quasi-experimental study, conducted by a team led by Dr Gil Rodriguez-Caravaca, Hospital Universitario Fundación Alcorcón, Madrid, Spain, performed cataract surgery on 19463 patients – 6595 patients before October 2005 and 12868 patients after. Each patient received intracameral cefuroxime as the endophthalmitis prophylaxis during cataract surgery.

Endophthalmitis was identified in 44 cases and positive microbiology was found in 29 cases, with the overall cumulative incidence being 0.23 cases per 100 patients.

Cefuroxime prevented endophthalmitis with a 95% confidence interval. It is an economical solution at €1 per dose, with a potential saving of €11777 for every 182 patients treated.

For more information please refer to the Journal of Cataract and Refractive Surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.